ABG Stock Chart & Stats
€270.90
€6.65(3.05%)
At close: 4:00 PM EST
€270.90
€6.65(3.05%)
Day’s Range― - ―
52-Week Range€212.90 - €325.25
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€52.83B
Enterprise Value€71.71K
Total Cash (Recent Filing)€2.24B
Total Debt (Recent Filing)€12.39B
Price to Earnings (P/E)23.6
Beta-0.04
Next Earnings
Aug 05, 2026EPS Estimate
3.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.12
Shares Outstanding194,561,070
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio7.05
Price to Book (P/B)40.17
Price to Sales (P/S)0.19
P/FCF Ratio18.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€305.60Price Target Upside12.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)15.59
Revenue Forecast (FY)€295.52B
Bulls Say, Bears Say
Bulls Say
Scale & Distribution NetworkCencora’s large-scale global distribution platform creates durable purchasing leverage, logistics efficiency and deep customer relationships across pharmacies, hospitals and health systems. That scale supports stable volume-driven margins, negotiating power with manufacturers and high entry barriers for competitors.
Specialty & International MomentumStrong international growth and expanding global specialty logistics (including cell & gene and lab logistics) diversify revenue toward higher-value services. These capabilities increase long-term revenue mix quality, support margin uplift, and deepen sticky manufacturer partnerships that are hard to replicate.
Robust Cash Generation & Capital ActionsConsistent operating cash flow and multi-billion annual free cash flow guidance provide capacity for debt reduction, targeted M&A and shareholder returns. Predictable cash generation supports reinvestment in specialty services and logistics while enabling opportunistic buybacks without abandoning core investments.
Bears Say
Elevated LeverageHigh leverage increases interest burden and reduces financial flexibility, limiting the company’s ability to fund investments or weather extended industry pressures. Volatile equity history (including negative equity in 2022) amplifies balance-sheet risk and makes covenant and refinancing exposure a persistent concern.
Free Cash Flow DeclineA notable step-down in trailing free cash flow reflects higher working-capital needs or timing shifts, reducing the buffer for debt paydown and acquisitions. Sustained FCF erosion would pressure capital allocation priorities and could force slower deleveraging or reduced shareholder returns.
Structural Revenue HeadwindsManufacturer list-price cuts, customer account losses and faster brand conversions materially pressure top-line growth. Even if mix changes support margins, persistent pricing and customer shifts can erode wholesale volumes and revenue durability, complicating long-term growth targets and forecasting.
Cencora News
ABG FAQ
What was Cencora, Inc.’s price range in the past 12 months?
Cencora, Inc. lowest stock price was €212.90 and its highest was €325.25 in the past 12 months.
What is Cencora, Inc.’s market cap?
Cencora, Inc.’s market cap is €52.83B.
When is Cencora, Inc.’s upcoming earnings report date?
Cencora, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 8 days.
How were Cencora, Inc.’s earnings last quarter?
Cencora, Inc. released its earnings results on May 06, 2026. The company reported €4.176 earnings per share for the quarter, missing the consensus estimate of €4.236 by -€0.06.
Is Cencora, Inc. overvalued?
According to Wall Street analysts Cencora, Inc.’s price is currently Undervalued.
Does Cencora, Inc. pay dividends?
Cencora, Inc. does not currently pay dividends.
What is Cencora, Inc.’s EPS estimate?
Cencora, Inc.’s EPS estimate is 3.82.
How many shares outstanding does Cencora, Inc. have?
Cencora, Inc. has 194,561,070 shares outstanding.
What happened to Cencora, Inc.’s price movement after its last earnings report?
Cencora, Inc. reported an EPS of €4.176 in its last earnings report, missing expectations of €4.236. Following the earnings report the stock price went up 0.311%.
Which hedge fund is a major shareholder of Cencora, Inc.?
Currently, no hedge funds are holding shares in DE:ABG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cencora Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€305.60 (12.81% Upside)
€305.60 (12.81% Upside)
Blogger Sentiment
Bullish
DE:ABG Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €2.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.49%
12-Months-Change
Fundamentals
Return on Equity
0.76%
Trailing 12-Months
Asset Growth
14.69%
Trailing 12-Months
Company Description
Cencora, Inc.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
ABG Company Deck
ABG Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced strong profitability and cash-generation metrics (EPS growth +7.5%, gross profit +16%, operating income +6%), a raised EPS range, improved operating income guidance, robust international performance, and the resumption of $1B share repurchases against material near-term revenue pressures (reduced consolidated revenue guidance from 7%–9% to 4%–6%) driven by WAC price reductions, account losses and faster mail-order brand conversions. Management highlighted transitory items (weather, COVID vaccine comparisons) and acquisition-related expense impacts but maintained confidence in long-term operating income growth and free cash flow generation.View all DE:ABG earnings summariesABG Revenue Breakdown
90.55% U.S. Healthcare Solutions
9.45% International Healthcare Solutions
>-0.01% Intersegment eliminations

ABG Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€305.60
▲(12.81% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Cardinal Health
―
Henry Schein
―
McKesson
―
Prestige Consumer Healthcare
―
Guardian Pharmacy Services, Inc. Class A
―









